deltatrials
Recruiting PHASE2 Interventional 2-arm NCT04288310

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

A Randomized, Double Blind, Placebo-controlled Phase 2b Study to Evaluate Efficacy, Pharmacokinetics, and Safety of 48-week Study Intervention With JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Sponsor: Janssen Sciences Ireland UC

Conditions Hepatitis B, Chronic
Interventions Entecavir (ETV) monohydrate JNJ-56136379 JNJ-73763989 Placebo for JNJ-56136379 Placebo for JNJ-73763989 Tenofovir alafenamide (TAF) Tenofovir disoproxil fumarate (TDF)
Updated 1 time since 2020 Last updated: Feb 26, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04288310, this PHASE2 trial focuses on Hepatitis B, Chronic and remains actively recruiting participants. Sponsored by Janssen Sciences Ireland UC, it has been updated 1 time since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Mar 2020 – present · 75 months · monthly snapshotRecruiting

Change History

1 version recorded
Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Sciences Ireland UC
Data source: Janssen Sciences Ireland UC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Antwerpen, Belgium , Barcelona, Spain , Berlin, Germany , Birmingham, United Kingdom , Bruxelles, Belgium , Bydgoszcz, Poland , Clichy, France , Crumpsall, United Kingdom , Edegem, Belgium , Essen, Germany and 27 more locations